抗合成酶综合征相关间质性肺疾病的管理与结局:系统文献综述
该系统文献综述纳入10篇文章共514例抗合成酶综合征相关间质性肺疾病(ASS-ILD)患者,汇总治疗与结局。基线用力肺活量(FVC)合并估计为预计值60.8%,一氧化碳弥散量(DLco)为49.8%;治疗1年后FVC较基线改善14.1%、DLco改善15.1%,配对t检验显示FVC(P=0.007)与DLco(P=0.002)均显著改善。作者认为各治疗间疗效无确定性差异,需更有力试验。
要点
- 基线FVC合并估计为预计值60.8%,DLco为49.8%。
- 治疗1年后FVC较基线改善14.1%,DLco改善15.1%。
- 作者认为各治疗间疗效无确定性差异,需更有力试验。
核心结论
- 该系统文献综述首次总结ASS-ILD的管理与结局,发现各治疗间疗效无确定性差异。
- 作者认为需更有力试验以降低ASS-ILD所致患病与死亡。
研究设计与样本
- 系统文献综述(注册号CRD42023416414),检索1946年至2023年9月发表的ASS-ILD管理与结局文章。
- 由两名评价者筛选与提取数据,纳入10篇文章共514例患者。
- 采用随机效应模型进行Meta分析,并酌情用配对t检验评估肺功能检查的治疗后变化。
主要发现
- 514例患者中女性67.8%,平均年龄52.4岁(标准差4.6)。
- 447例(86.9%)有基线高分辨率CT记录,最常见模式为非特异性间质性肺炎(n=220;49.2%)。
- 最常见肌炎相关自身抗体为抗Jo1(48%),27.8%伴抗Ro52抗体。
- Meta分析合并估计基线FVC为预计值60.8%(标准误2.1),DLco为49.8%(标准误3.5)。
- 1年后FVC较基线合并改善14.1%(标准误3.1),DLco改善15.1%(标准误2.8);配对t检验显示FVC(P=0.007)与DLco(P=0.002)总体显著改善。
关键数值与推荐
- 基线FVC合并估计为预计值60.8%(标准误2.1),DLco为49.8%(标准误3.5)。
- 1年后FVC较基线改善14.1%(标准误3.1),DLco改善15.1%(标准误2.8)。
- 利妥昔单抗者1年FVC改善12.2%、DLco增加2.9%;环磷酰胺者FVC改善17%、DLco增加6.3%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者认为需更有力试验以降低ASS-ILD所致患病与死亡。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Anti-synthetase syndrome (ASS) is a chronic autoimmune condition, with interstitial lung disease (ILD) being a key feature. This systematic literature review (SLR; CRD42023416414) aimed to summarize treatments and outcomes of ILD associated with ASS (ASS-ILD). METHODS: Databases were searched for articles discussing ASS-ILD management and outcomes, published 1946-September 2023. Screening and data extraction were performed by two reviewers. Meta-analysis, using a random effects model, and paired t-tests were undertaken where appropriate to evaluate post-treatment-change in pulmonary function tests. RESULTS: Ten articles were included, comprising 514 patients: 67.8% female, mean age 52.4 years (s.d. 4.6). Baseline high-resolution CT was documented in 447 patients (86.9%); the most common pattern was non-specific interstitial pneumonia (n = 220; 49.2%). The most common myositis-associated autoantibody was anti-Jo1 (48%), with 27.8% having associated anti-Ro52 antibodies. Pooled estimate, after meta-analysis, for baseline forced vital capacity (FVC) was 60.8% predicted (s.e. 2.1) and for diffusion capacity of lungs for carbon monoxide (DLco) was 49.8% (s.e. 3.5). After 1 year, pooled improvement in FVC was 14.1% from baseline (s.e. 3.1) and in DLco was 15.1% (s.e. 2.8). Paired t-test demonstrated significant overall improvement in FVC (P = 0.007) and DLco (P = 0.002). Patients receiving rituximab had 12.2% improvement in FVC and 2.9% increase in DLco at 1 year; for patients receiving CYC, there was 17% improvement and 6.3% increase, respectively. Twenty-eight deaths were reported. CONCLUSION: Our SLR, the first to summarize management and outcomes of ASS-ILD, found no conclusive difference between effectiveness of treatments. More robust trials are required to reduce morbidity and mortality resulting from ASS-ILD.
引用
- Kouranloo K, Dey M, Elwell H, et al. Management and outcomes of interstitial lung disease associated with anti-synthetase syndrome: a systematic literature review. Rheumatology (Oxford). 2025. PMID: 39083028. doi:10.1093/rheumatology/keae403
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。